IBAB (IBAB) News
Follow IBAB (IBAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
IBA Signs Contract To Install First Proton Therapy Center In Rome, Italy
Ion Beam Applications SA EURONEXT:IBAB
NEWS | Sep 29, 2026, 05:04 AM UTC
L
Ion Beam Applications S.A. (IBAB) Wins Rome Proton Therapy Contract
Ion Beam Applications S.A. signed a contract with IFO to deliver a turnkey Proteus ONE proton therapy system in Rome, with patient treatments expected in 2030. Typical end-user price for such systems with multiyear maint
NEWS | Sep 29, 2026, 05:01 AM UTC
L
IBA signs contract to install the first proton therapy center in central Italy, in Rome
Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions
NEWS | Sep 29, 2026, 05:01 AM UTC
L
Ion Beam Applications S.A. (IBAB) Forms JV With Penn Medicine
Ion Beam Applications S.A. and Penn Medicine formed Noventra Oncology Alliance, a JV offering advisory and lifecycle services to develop and optimize proton therapy and advanced radiation oncology programs.Material Detai
NEWS | Sep 28, 2026, 05:08 AM UTC
L
IBA, Penn Medicine Announce Noventra Oncology Alliance Joint Venture
Ion Beam Applications SA EURONEXT:IBAB
NEWS | Sep 28, 2026, 05:03 AM UTC
L
Penn Medicine and IBA Launch Joint Venture to Advance Proton Therapy and Radiation Oncology Program Development Worldwide
New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecyclePHILADELPHIA, Pa., and LOUVA
NEWS | Sep 28, 2026, 05:01 AM UTC
L
Ion Beam Applications S.A. (IBAB) Launches QUASAR Penta-Guide QA Phantom
Ion Beam Applications S.A. launched the QUASAR Penta-Guide Performance Phantom, enabling 25+ imaging and machine QA tests in one setup with integrated analysis software for radiotherapy workflows.Material DetailsContext
NEWS | Sep 27, 2026, 12:08 PM UTC
L
IBA Launches QUASAR® Penta-Guide Performance Phantom
More than 25 imaging and machine QA tests in one setup.Louvain-la-Neuve, Belgium, 27 September 2026 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider
NEWS | Sep 27, 2026, 12:08 PM UTC
L
IBA to coordinate LIFEDESTINY, a new European LIFE project to advance sustainable PFAS remediation
Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new Europea
NEWS | Sep 25, 2026, 05:08 AM UTC
L
IBA — TRANSPARENCY NOTIFICATION
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, September 8, 2026 06:00 PMSummary of the notificationIBA (Ion Beam Applications), the world’s leading provi
EQUITY | Sep 08, 2026, 04:07 PM UTC
L
IBA joins PFAROS European initiative on PFAS destruction
IBA says it is participating in PFAROS, a new European research and innovation initiative targeting environmental emissions and exposure, with healthcare and pharmaceutical applications.
EQUITY | Sep 02, 2026, 05:07 AM UTC
L
IBAB to co-lead PFAROS initiative
Ion Beam Applications SA says it will co-lead the PFAROS initiative.
EQUITY | Sep 02, 2026, 05:02 AM UTC
L
IBAB reports H1 2026 revenue and margin growth
IBAB said H1 2026 revenue and margin grew, citing robust proton therapy orders and reaffirmed guidance.
EARNINGS | Aug 27, 2026, 03:11 PM UTC
M
IBAB reports strong H1 2026 revenue and profitability growth
TradingView reports IBAB saw strong revenue and profitability growth in H1 2026, alongside robust proton therapy momentum.
EQUITY | Aug 27, 2026, 02:18 PM UTC
M
IBAB reports strong H1 2026 with 6% revenue growth
IBAB said H1 2026 revenue rose 6% with improved margins and robust order intake.
EQUITY | Aug 27, 2026, 01:07 PM UTC
M
IBA H1 revenue up 6% on equipment order intake growth
IBA said H1 revenue rose 6%, citing growth in equipment order intake.
EQUITY | Aug 27, 2026, 05:09 AM UTC
L
IBAB cites strong H1 growth and reaffirms EBIT guidance
IBAB says H1 growth and profitability were driven by Proton Therapy, reaffirming its EBIT guidance.
EARNINGS | Aug 27, 2026, 05:07 AM UTC
M
IBA reports Half Year 2026 results
IBA reported Half Year 2026 results, saying they are on track with its improved profitability trajectory.
EQUITY | Aug 27, 2026, 05:07 AM UTC
L
IBAI H1 total net sales €323.7 mln; Outlook 2026 confirmed
IBAI reported H1 total net sales of €323.7 mln and confirmed Outlook 2026.
EARNINGS | Aug 27, 2026, 05:05 AM UTC